Xiidra from Shire Pharmaceuticals was released this July to treat inflammatory dry eye. Dry eye disease is a condition that affects 10-15 percent of all Americans. The optometry community is excited to have another option for it's treatment.
Read the FDA statement here. The effectivity of Xiidra was confirmed in a double blind study of thousands of patients ages 19-97 compared against a placebo treatment.
Xiidra is not yet covered by Medicare or other vision and medical insurances.